Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Klichinsky

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|December 13, 2021
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid TumorsChristopher Sloas, Saar Gill, Michael Klichinsky
Plos Pathogens|August 11, 2011
EBV latency types adopt alternative chromatin conformationsItalo Tempera, Michael Klichinsky, Paul M Lieberman
Cancer Research|November 18, 2020
Macrophage-Based Approaches for Cancer ImmunotherapyNicholas R Anderson, Nicholas G Minutolo, Saar Gill, et al.
Cell Host & Microbe|August 21, 2012
An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactionsAaron Arvey, Italo Tempera, Kevin Tsai, et al.
Cancer Discovery|June 4, 2017
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T CellsMarco Ruella, Michael Klichinsky, Saad S Kenderian, et al.
Nature Communications|April 14, 2015
A fungal protease allergen provokes airway hyper-responsiveness in asthmaNariman A Balenga, Michael Klichinsky, Zhihui Xie, et al.
Science Translational Medicine|September 10, 2025
Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitisHongxue Shi, Xiaobo Wang, Christopher Sloas, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|December 13, 2021
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid TumorsChristopher Sloas, Saar Gill, Michael Klichinsky
Plos Pathogens|August 11, 2011
EBV latency types adopt alternative chromatin conformationsItalo Tempera, Michael Klichinsky, Paul M Lieberman
Cancer Research|November 18, 2020
Macrophage-Based Approaches for Cancer ImmunotherapyNicholas R Anderson, Nicholas G Minutolo, Saar Gill, et al.
Cell Host & Microbe|August 21, 2012
An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactionsAaron Arvey, Italo Tempera, Kevin Tsai, et al.
Cancer Discovery|June 4, 2017
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T CellsMarco Ruella, Michael Klichinsky, Saad S Kenderian, et al.
Nature Communications|April 14, 2015
A fungal protease allergen provokes airway hyper-responsiveness in asthmaNariman A Balenga, Michael Klichinsky, Zhihui Xie, et al.
Science Translational Medicine|September 10, 2025
Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitisHongxue Shi, Xiaobo Wang, Christopher Sloas, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Pageof 2